"For centuries, malaria has stolen children from their parents, and health, wealth and hope from communities. But today, the story is changing."
"Coartem Baby contains two antimalarial drugs, artemether and lumefantrine, and was developed by the multinational pharmaceutical company Novartis and the Medicines for Malaria Venture (MMV)."
"For too long, newborns and young infants with malaria have fallen through the cracks because they were treated with formulations designed for older children."
"The WHO said infants with malaria had until now been treated with formulations designed for older children which increase the risk of dosing errors, side effects and toxicity."
The World Health Organization has approved Coartem Baby, the first malaria treatment specifically for infants, addressing a significant health gap. In Africa, up to 18% of children under six months are infected with malaria, leading to high mortality rates. Coartem Baby is designed for infants as small as 2kg and comes in a sweet cherry-flavored tablet form that can be mixed with liquids. This approval allows for public-sector procurement in malaria-endemic regions, particularly sub-Saharan Africa, and aims to improve treatment safety and efficacy for young children.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]